Solriamfetol: A Potential New Treatment for Adult ADHD
A recent pilot study has explored the potential of solriamfetol as a treatment for adults with attention-deficit/hyperactivity disorder (ADHD). The study aimed to determine the drug’s efficacy and tolerability.
HCN Medical Memo
The results of this pilot study suggest that solriamfetol could be a promising new treatment option for adults with ADHD. Healthcare professionals should consider this when exploring treatment options for patients who may not tolerate or adequately respond to currently available treatments.
- The study was a remotely conducted, randomized, double-blind, placebo-controlled, 6-week dose-optimization trial.
- Sixty adults diagnosed with DSM-5 ADHD participated from August 2021 through January 2023.
- Participants were administered either 75 mg or 150 mg of solriamfetol.
This is one of the first studies to explore the use of solriamfetol, a drug typically used to treat sleep disorders, as a potential treatment for ADHD.
- Solriamfetol was well tolerated with no significant effect on mean heart rate, systolic blood pressure, or diastolic blood pressure.
- Adverse events were not significantly different from those on placebo.
- By the study endpoint, a greater proportion of individuals in the treatment group met the a priori–defined treatment response.
- Those treated with solriamfetol also had greater improvement in total AISRS scores by week 3 through week 6.
More on ADHD